Intelligent Bio Solutions Inc. (INBS) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.43
↓-71% vs avg
5yr avg: 1.46
30Y Low0.1·High3.3
ROE
↓
-192.2%
↑-21% vs avg
5yr avg: -158.4%
30Y Low-208%·High-77%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
INBS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Intelligent Bio Solutions Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $907066 | $611520 | $7M | $12M | $49M | — | — | — | — |
| Enterprise Value | $2M | $168962 | $-4546304 | $7M | $3M | $37M | — | — | — | — |
| P/E Ratio → | -0.11 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.93 | 0.30 | 0.20 | 5.33 | — | 24.87 | — | — | — | — |
| P/B Ratio | 0.43 | 0.32 | 0.07 | 1.82 | 1.78 | 3.28 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
INBS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.06 | -1.46 | 5.63 | — | 18.52 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
INBS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Intelligent Bio Solutions Inc. earns an operating margin of -348.7%. Operating margins have expanded from -1002.1% to -348.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -192.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 40.8% | 40.8% | 45.8% | 26.0% | — | 100.0% | 100.0% | — | — | — |
| Operating Margin | -348.7% | -348.7% | -330.5% | -1002.1% | — | -281.4% | -1513.7% | — | — | — |
| Net Profit Margin | -346.2% | -346.2% | -326.4% | -845.9% | — | -355.3% | -1676.2% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -192.2% | -192.2% | -171.1% | -207.8% | -77.1% | -143.7% | — | — | — | — |
| ROA | -96.0% | -96.0% | -84.2% | -93.6% | -48.6% | -57.8% | -131.7% | -304.2% | -317.4% | -51.0% |
| ROIC | -313.0% | -313.0% | -217.5% | -796.3% | -1689.0% | -434.4% | -956.9% | -378.2% | -254.3% | — |
| ROCE | -189.6% | -189.6% | -160.7% | -207.2% | -64.5% | -86.0% | — | — | — | — |
INBS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $1M exceeds total debt of $281805, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.14 | 0.52 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 224.77 |
| Net Debt / Equity | — | -0.26 | -0.63 | 0.10 | -1.26 | -0.84 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | 221.21 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -174.82 | -174.82 | -61.52 | -56.35 | -1105.83 | -5.09 | -6.24 | -8.78 | -10.14 | — |
Net cash position: cash ($1M) exceeds total debt ($281805)
INBS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.77x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.66x to 0.77x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.77 | 0.77 | 1.57 | 0.66 | 2.33 | 4.94 | 0.06 | 0.37 | 0.45 | 0.10 |
| Quick Ratio | 0.65 | 0.65 | 1.42 | 0.49 | 2.33 | 4.94 | 0.06 | 0.05 | 0.08 | 0.10 |
| Cash Ratio | 0.19 | 0.19 | 1.16 | 0.26 | 1.78 | 3.41 | 0.06 | 0.03 | 0.08 | 0.01 |
| Asset Turnover | — | 0.37 | 0.23 | 0.12 | — | 0.09 | 0.08 | — | — | — |
| Inventory Turnover | 2.84 | 2.84 | 2.17 | 0.95 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 191.21 | 114.76 | 241.95 | — | 386.82 | 37.89 | — | — | — |
INBS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Intelligent Bio Solutions Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $527364 | $318500 | $200900 | $73326 | $52074 | $70920 | $60396 | $60396 | $60396 |
Peer Comparison
Compare INBS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 INBSYou | $3M | -0.1 | — | — | 40.8% | -348.7% | -192.2% | -313.0% | — |
 OPRX | $124M | 24.6 | 6.5 | 6.6 | 67.3% | 10.7% | 4.2% | 7.1% | 0.3 |
 QDEL | $733M | -0.6 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 CUE | $94M | -4.3 | — | — | 87.3% | -96.7% | -121.1% | -537.6% | — |
 SEER | $105M | -1.4 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 IDXX | $45B | 43.7 | 31.6 | 43.1 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 GKOS | $8B | -40.9 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See INBS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INBS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INBS vs OPRX
Side-by-side business, growth, and profitability comparison vs OptimizeRx Corporation.
Start ComparisonINBS — Frequently Asked Questions
Quick answers to the most common questions about buying INBS stock.
What is Intelligent Bio Solutions Inc.'s P/E ratio?
Intelligent Bio Solutions Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Intelligent Bio Solutions Inc.'s ROE?
Intelligent Bio Solutions Inc.'s return on equity (ROE) is -192.2%. The historical average is -158.4%.
Is INBS stock overvalued?
Based on historical data, Intelligent Bio Solutions Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Intelligent Bio Solutions Inc.'s profit margins?
Intelligent Bio Solutions Inc. has 40.8% gross margin and -348.7% operating margin.